RxDoctor Payments Data

Kristine Reinhardt

Family · Boise, IDNPI 1639490006

Payments from drug & device makers

$716in general payments, 2019–2025

Across 22 payments — averaging $32.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$204
  • Phathom Pharmaceuticals, Inc.$111
  • Novo Nordisk$87
  • Pfizer$54
  • Astellas Pharma US Inc$30
  • Dexcom, Inc.$26
  • plus $205 from 10 others

What the payments were for

  • Food & beverage$716100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$716 in reported general payments places this provider in the 65th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$37,924
Medicare patients
160
Services billed
521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$116,856
OzempicSemaglutide101$103,252
FarxigaDapagliflozin Propanediol90$89,947
MounjaroTirzepatide19$28,955
XareltoRivaroxaban22$19,963
JardianceEmpagliflozin11$16,072
MyrbetriqMirabegron20$10,676
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen269$6,800
SymbicortBudesonide/Formoterol Fumarate20$6,210
Levothyroxine Sodium631$5,596
Tolterodine Tartrate ErTolterodine Tartrate13$5,012
Gabapentin255$4,577
Atorvastatin Calcium519$4,505
Omeprazole281$4,081
Varenicline Tartrate14$3,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$116,856131 claims
Novo NordiskOzempic$87$103,252101 claims
AstraZenecaFarxiga, Symbicort$204$96,157110 claims
Lilly USA, LLCMounjaro$16$28,95519 claims
Astellas Pharma US IncMyrbetriq$30$10,67620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 809 family providers in Idaho.

Other family in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →